An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...

It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...

The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the company announced Monday. Patrizia Cavazzoni was formerly director ...

Shares of Pfizer (NYSE:PFE) have delivered negative returns since I started covering the stock and the last four months have not been great either as it is down another 12% since my previous ...

Feb 24 (Reuters) - Pfizer (PFE.N), opens new tab on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing ...

NEW YORK/TOKYO -- Pfizer will end global development and commercialization of Beqvez, a gene therapy for hemophilia, after the drugmaker dropped its other similar treatment for the disorder in ...

After leaving the FDA, where she served as director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., is returning to her previous employer: Big Pharma Pfizer. After ...

Pfizer's EPS and revenue beat my expectations, mainly due to strong sales of its anti-cancer medications. So, Xtandi sales amounted to $565 million in the fourth quarter of 2024, an increase of 79 ...

Patrizia Cavazzoni, formerly the top regulator of the drug division of the Food and Drug Administration, will join Pfizer as chief medical officer, a role in which she will lead the drug firm’s ...

Feb 20 (Reuters) - Pfizer (PFE.N), opens new tab said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and ...